✓ Translated by DotMD AI Clinical Council Source: Addictive behaviors • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #41237599 ↗

Phase III Randomized Trial: Witnessed overdose history and response among overdose survivors who use non-prescribed opioids in an overdose prevention trial

Original Paper Title: “Witnessed overdose history and response among overdose survivors who use non-prescribed opioids in an overdose prevention trial”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Most REBOOT participants witnessed a recent opioid overdose preceding enrollment. After enrollment, nearly all witnessed overdoses were responded to; the intervention had no effect on whether the participant personally responded. Given near-universal response, there was little room for improving overdose response.
Study Design & Sample: Phase III Randomized Trial published in Addictive behaviors (Multi-cohort synthesis).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Addictive behaviors (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: The REpeated-dose Behavioral intervention to reduce Opioid Overdose Trial (REBOOT) evaluated motivational interviewing for overdose prevention, focusing partly on witnessed overdose response. Key clinical takeaway: Most REBOOT participants witnessed a recent opioid overdose preceding enrollment. After enrollment, nearly all witnessed overdoses were responded to; the intervention had no effect on whether the participant personally responded. Given near-universal response, there was little room for improving overdose response.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Addictive behaviors, 2026-02-15; Phase III Randomized Trial; Rigor 82/100): Most REBOOT participants witnessed a recent opioid overdose preceding enrollment. After enrollment, nearly all witnessed overdoses were responded to; the intervention had no effect on whether the participant personally responded. Given near-universal response, there was little room for improving overdose response.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: naloxone-hydrochloride → Rx: naloxone-hcl → Condition: genetic-brain-disorders → Condition: health-checkup →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41237599: Phase III Randomized Trial: Witnessed overdose history and response among overdose survivors who use non-prescribed opioids in an overdose prevention trial

3 of 3 Free Questions Remaining